Shares of Impax Laboratories Inc (NASDAQ:IPXL) have been given a consensus recommendation of “Hold” by the nineteen research firms that are presently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $20.78.
A number of equities research analysts have issued reports on the stock. ValuEngine cut shares of Impax Laboratories from a “hold” rating to a “sell” rating in a report on Monday, April 2nd. Zacks Investment Research cut shares of Impax Laboratories from a “hold” rating to a “sell” rating in a report on Tuesday, March 27th. BidaskClub raised shares of Impax Laboratories from a “sell” rating to a “hold” rating in a report on Wednesday, March 14th. SunTrust Banks assumed coverage on shares of Impax Laboratories in a report on Wednesday, March 7th. They set a “buy” rating and a $24.00 target price on the stock. Finally, Royal Bank of Canada set a $20.00 price target on shares of Impax Laboratories and gave the company a “hold” rating in a research report on Friday, March 2nd.
A number of large investors have recently made changes to their positions in IPXL. Xact Kapitalforvaltning AB purchased a new position in Impax Laboratories in the fourth quarter worth $198,000. BlueCrest Capital Management Ltd purchased a new position in Impax Laboratories in the fourth quarter worth $336,000. Envestnet Asset Management Inc. grew its position in Impax Laboratories by 470.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 20,581 shares of the specialty pharmaceutical company’s stock worth $343,000 after acquiring an additional 16,976 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in Impax Laboratories in the fourth quarter worth $393,000. Finally, Commerce Bank grew its position in Impax Laboratories by 112.7% in the fourth quarter. Commerce Bank now owns 24,375 shares of the specialty pharmaceutical company’s stock worth $406,000 after acquiring an additional 12,915 shares in the last quarter. Institutional investors own 90.40% of the company’s stock.
Shares of IPXL stock opened at $18.95 on Wednesday. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 4.11. Impax Laboratories has a 1 year low of $12.45 and a 1 year high of $25.70. The firm has a market cap of $1,441.76, a price-to-earnings ratio of 30.08, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17.
Impax Laboratories (NASDAQ:IPXL) last issued its earnings results on Thursday, March 1st. The specialty pharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.01). Impax Laboratories had a negative net margin of 60.49% and a positive return on equity of 10.42%. The business had revenue of $182.90 million for the quarter, compared to the consensus estimate of $199.13 million. During the same period in the previous year, the firm earned $0.16 EPS. The company’s revenue was down 7.8% compared to the same quarter last year. sell-side analysts expect that Impax Laboratories will post 1.21 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Impax Laboratories Inc (IPXL) Receives $20.78 Average Price Target from Brokerages” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/impax-laboratories-inc-ipxl-receives-20-78-average-price-target-from-brokerages.html.
About Impax Laboratories
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.